Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the TAT8-TK as a late gene in a pancreatic tumour model

Gene Therapy volume 14, pages 1471–1480 (2007)Cite this article

Abstract

Replication-competent adenoviruses carrying the herpes simplex thymidine kinase (TK) gene have shown contradictory evidence with regard to their antitumoural efficacy in combination with ganciclovir (GCV) treatment. We generated a replication-competent adenovirus carrying Tat8-TK, a modified form of the TK gene, under the control of the adenoviral major late promoter (AdRGDTat8-TK-L). Pancreatic cancer cell lines with different sensitivity to the TK/GCV system were infected with AdRGDTat8-TK-L, both in the presence and absence of GCV, and tested for treatment efficacy. We observed that, although the presence of GCV reduced viral replication in all infected cell lines, in three out of four GCV significantly enhanced the efficacy of the virotherapy. Interestingly, the cytotoxicity of the AdRGD-Tat8-TK-L/GCV was found more potent than that of a first generation AdTK/GCV system. In tumour xenografts from BxPC-3 and NP-18 pancreatic cells, both AdRGDTat8-TK-L and AdRGDTat8-TK-L/GCV treatment showed antitumoural activity. In BxPC-3 tumours scheduling of virus and prodrug was a key factor to determine the outcome of the therapy. Importantly, the addition of GCV enhanced the antitumoural effect of AdRGDTat8-TK-L only when applied in two rounds of virus+GCV. Interestingly, in spite of interfering with viral replication in vitro, GCV treatment of NP-18 tumours did not compromise the antitumoural efficacy of the AdRGDTat8-TK-L adenovirus. Thus, our results show that the combination therapy of a replicative adenovirus and the Tat8-TK/GCV suicide system can prove beneficial, when the appropriate regimen of virus and GCV is applied.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Alemany R, Balague C, Curiel DT . Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723–727.

    Article  CAS  PubMed  Google Scholar 

  2. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359–6366.

    CAS  PubMed  Google Scholar 

  3. Vecil GG, Lang FF . Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 2003; 65: 237–246.

    Article  PubMed  Google Scholar 

  4. Heise C, Lemmon M, Kirn D . Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res 2000; 6: 4908–4914.

    CAS  PubMed  Google Scholar 

  5. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [see comments]. 2000; 6: 879–885.

  6. You L, Yang CT, Jablons DM . ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000; 60: 1009–1013.

    CAS  PubMed  Google Scholar 

  7. Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM . Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Therapy 1999; 6: 57–62.

    Article  CAS  PubMed  Google Scholar 

  8. Wildner O, Blaese RM, Morris JC . Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59: 410–413.

    CAS  PubMed  Google Scholar 

  9. Wildner O, Morris JC . The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res 2000; 60: 4167–4174.

    CAS  PubMed  Google Scholar 

  10. Morris JC, Wildner O . Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56–62.

    Article  CAS  PubMed  Google Scholar 

  11. Lambright ES, Amin K, Wiewrodt R, Force SD, Lanuti M, Propert KJ et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Therapy 2001; 8: 946–953.

    Article  CAS  PubMed  Google Scholar 

  12. Hakkarainen T, Hemminki A, Curiel DT, Wahlfors J . A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy. Int J Mol Med 2006; 18: 751–759.

    CAS  PubMed  Google Scholar 

  13. Cascante A, Huch M, Rodríguez LG, González JR, Costantini L, Fillat C . Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression in vivo. Hum Gene Ther 2005; 16: 1377–1388.

    Article  CAS  PubMed  Google Scholar 

  14. Garcia-Castro J, Martínez-Palacio J, Lillo R, García-Sánchez F, Alemany R, Madero L et al. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Ther 2005; 12: 341–349.

    Article  CAS  PubMed  Google Scholar 

  15. Esandi MC, van Someren GD, Vincent AJ, van Bekkum, DW, Valerio D, Bout A et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Therapy 1997; 4: 280–287.

    Article  CAS  PubMed  Google Scholar 

  16. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C . Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 2003; 7: 851–858.

    Article  CAS  PubMed  Google Scholar 

  17. Vincent AJ, Esandi MC, Avezaat CJ, Vecht CJ, Sillevis Smitt P, van Bekkum DW et al. Preclinical testing of recombinant adenoviral herpes simplex virus-thymidine kinase gene therapy for central nervous system malignancies. Neurosurgery 1997; 41: 442–451; discussion 451–442.

    Article  CAS  PubMed  Google Scholar 

  18. Suzuki K Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R . A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120–126.

    PubMed  Google Scholar 

  19. Carrio M, Romagosa A, Mercade E, Mazo A, Nadal M, Gómez-Foix AM et al. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Therapy 1999; 6: 547–553.

    Article  CAS  PubMed  Google Scholar 

  20. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO . Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 2000; 11: 67–76.

    Article  CAS  PubMed  Google Scholar 

  21. Chu RL, Post DE, Khuri FR, Van Meir EG . Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299–5312.

    Article  CAS  PubMed  Google Scholar 

  22. Carrio M, Mazo A, López-Iglesias C, Estivill X, Fillat C . Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: implications for gene therapy. Int J Cancer 2001; 94: 81–88.

    Article  CAS  PubMed  Google Scholar 

  23. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706–9713.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Villanueva A, Garcia C, Paules AB, Vicente M, Megías M, Reyes G et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998; 17: 1969–1978.

    Article  CAS  PubMed  Google Scholar 

  25. Majem M, Cascallo M, Bayo-Puxan N, Mesia R, Germa JR, Alemany R . Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD. Cancer Gene Ther 2006; 13: 696–705.

    Article  CAS  PubMed  Google Scholar 

  26. Alemany R, Curiel DT . CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Therapy 2001; 8: 1347–1353.

    Article  CAS  PubMed  Google Scholar 

  27. Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, Alemany R . Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 2006; 87: 2487–2495.

    Article  CAS  PubMed  Google Scholar 

  28. Bewig B, Schmidt WE . Accelerated titering of adenoviruses. Biotechniques 2000; 28: 870–873.

    Article  CAS  PubMed  Google Scholar 

  29. Pinheiro JC, Bates DM . Mixed-Effects Models in S and S-PLUS. Springer-Verlag: New York, 2000.

    Book  Google Scholar 

Download references

Acknowledgements

This was supported by a grant from the Spanish Ministry of Education and Science, BIO2005–08682-C03–02/01 and received partial support from the Generalitat de Catalunya SGR0500008 and European Commission Theradpox contract LSHB-CT-2005–018700. A Cascante was supported by a pre-doctoral fellowship (FPU) granted by the Spanish Ministry of Education and Science, D Abate-Daga was a pre-doctoral fellow of the Fundación Carolina and Laura Garcia-Rodríguez was a pre-doctoral fellow (FI) of the Generalitat de Catalunya.

Author information

Authors and Affiliations

  1. Programa Gens i Malaltia, Centre de Regulació Genòmica-CRG, UPF, Parc de Recerca Biomèdica de Barcelona-PRBB, Barcelona, Spain

    A Cascante, D Abate-Daga, L Garcia-Rodríguez, J R González & C Fillat

  2. Laboratori de Recerca Translacional, IDIBELL- Institut Català d'Oncologia, Barcelona, Spain

    R Alemany

  3. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain

    C Fillat

Authors
  1. A Cascante
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Abate-Daga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Garcia-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J R González
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Alemany
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Fillat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Fillat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cascante, A., Abate-Daga, D., Garcia-Rodríguez, L. et al. GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the TAT8-TK as a late gene in a pancreatic tumour model. Gene Ther 14, 1471–1480 (2007). https://doi.org/10.1038/sj.gt.3303008

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3303008

Keywords

This article is cited by

Search

Advanced search

Quick links